The difference between the results for wild‐type and mutated PARK2 in this study was seen in the response to placebo+R‐CHOP rather than ibrutinib+R‐CHOP, suggesting that in wild‐type PARK2, chemotherapy can induce apoptosis via the death pathway, whereas this response is inhibited in PARK2‐mutated tumours, making them more resistant to chemotherapy. The gene discussed is PRKN; the disease is neoplasm.